# Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors

> **NCT00003478** · PHASE1,PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 10 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **PROCEDURE:** conventional surgery
- **RADIATION:** iodine I 131 monoclonal antibody 81C6
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00003478
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-10
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2013-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003478, "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00003478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*